US report finds flaws in FDA oversight of foreign clinical trials
This article was originally published in Scrip
The US Department of Health and Human Services has called for the Food and Drug Administration to improve its oversight of foreign clinical trial data after finding that sponsors rely "heavily" on such data to support their marketing applications and a lack of foreign trial inspections by the agency.
You may also be interested in...
Swissmedic says its good manufacturing practice certificates remain valid for longer than companies might assume. Separately, it is giving companies more time to conduct nitrosamine-related risk evaluations.
In the second segment of a two-part article on transparency provisions for the new EU clinical trial portal, a senior Merck executive explains how the company will ensure that commercially sensitive information and personal data in its clinical trial applications are not made public.
In the first of a two-part article on transparency provisions for the new EU clinical trial portal, the Pink Sheet reports on aspects that sponsors must consider to protect commercially confidential information in their clinical trial applications. The second article will look at the approach taken by Merck and discuss outstanding hot topics in relation to transparency and CTIS.